Five Prime Therapeutics, Inc.
FPRX
FPRX was delisted on the 15th of April, 2021.
172 hedge funds and large institutions have $1.26B invested in Five Prime Therapeutics, Inc. in 2016 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 57 increasing their positions, 73 reducing their positions, and 19 closing their positions.
104,300% more call options, than puts
Call options by funds: $1.04M | Put options by funds: $1K
2% less funds holding
Funds holding: 176 → 172 (-4)
9% less capital invested
Capital invested by funds: $1.39B → $1.26B (-$131M)
11% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 19
22% less repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 73
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$24.2M |
| 2 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$9.96M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$7.42M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$7.23M |
| 5 |
UBS AM
Chicago,
Illinois
|
+$6.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$29.7M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$21.8M |
| 3 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$17.5M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$11.8M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$10.8M |
FPRX Hedge Fund Activity: Q4 2016 in Review
172 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q4 2016, worth a combined $1.26B — down 9.4% from $1.39B a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of FPRX and 17 opened new positions — a net loss of 2 holders — while 73 trimmed existing stakes and 57 added.
The largest buyer was Vanguard Group, adding an estimated $24.2M. The largest seller was Goldman Sachs, cutting an estimated $29.7M.
- 172 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q4 2016, down from 176 in Q3 2016.
- Funds reported $1.26B of Five Prime Therapeutics, Inc. stock for Q4 2016, down 9.4% quarter-over-quarter.
- 17 funds opened new Five Prime Therapeutics, Inc. positions in Q4 2016 and 19 closed out, a net change of -2 holders.
- The largest Five Prime Therapeutics, Inc. buyer in Q4 2016 was Vanguard Group, an estimated $24.2M added.
- The largest Five Prime Therapeutics, Inc. seller in Q4 2016 was Goldman Sachs, an estimated $29.7M sold.
Based on aggregated 13F filings for Q4 2016.